Can Neko Health really scale like Spotify? Last updated: 31 July 2026 In our updated market reports , you will find everything you need SUMMARY Neko Health can become a major global preventive-health company, but it cannot scale like Spotify under its current one-hour, clinic-based delivery model. The company has already moved past the experimental-clinic stage. More than 100,000 completed scans, eight operating clinics and over 65 million in 2023, 700 million lately. That adds up to just over 7 billion, roughly four times its valuation at the previous round. Daniel Ek’s presence explains the nickname, but the comparison now goes deeper than having the same co-founder. Neko is trying to turn a fragmented, unpleasant healthcare task into a simple consumer experience, then reproduce it under one global brand. Spotify did something similar with music. The difficult part is that Neko still needs a clinic, medical equipment and clinical staff every time someone uses the service. If you want more recent data on this point, please see our latest preventive health screening market report . What would scaling like Spotify actually look like? In practical terms, Neko would need to grow its customer base much faster than its clinics, staffing costs and medical complexity. Spotify’s latest filed results show 761 million monthly active users, 293 million paying subscribers and a presence in 184 markets. A new listener can start within minutes without Spotify building a listening room or scheduling a professional for that person. A Neko customer currently spends about an hour inside a physical clinic. The visit includes skin imaging, cardiovascular measurements, a blood draw, on-site analysis and a consultation with a clinician. Expansion therefore requires rooms, machines, nurses, doctors, laboratory processes and local regulatory approval. There are three versions of the Spotify comparison. A globally recognized consumer brand looks plausible today, millions of recurring customers are possible, and digital-style economics remain far away under Neko’s current delivery model. Measure Spotify today Neko Health today What Neko must prove Reach 761 million monthly users A six-figure completed scan base Demand can grow from thousands to millions Geography 184 markets Eight operating clinics in two countries The same care model works across medical systems Customer frequency Often daily Mainly once a year People keep returning after several healthy scans Delivery Digital One-hour clinic visit Volume rises faster than rooms and staff Expansion cost Limited physical capacity per user New sites, devices and clinicians Software and automation carry more of the growth Is Neko Health growing unusually fast right now? Yes, Neko’s recent growth is exceptional for a business that has to examine every customer in person. When Neko announced its Series B in early 2025, it had completed 10,000 scans across Stockholm and London. The latest company figure is above 100,000, so its total scan count has grown more than tenfold in roughly a year and a half. Neko also said it delivered six times more scans in 2025 than in 2024. The clinic network has grown almost as fast. Neko now has two Stockholm clinics and six in the UK, covering four London locations plus Manchester and Birmingham. It started with one Stockholm site in 2023 and entered Britain in late 2024. Few private medical brands open that many sites, train hundreds of clinical employees and preserve one standardized customer journey so quickly. The growth also appears to extend beyond wealthy central London. Manchester opened with capacity for 20,000 annual scans, Birmingham followed with capacity for 25,000, and thousands had reportedly joined each local waitlist before opening. That gives us more confidence than another fashionable clinic in Marylebone would have. Nearly all this growth has come from adding physical capacity. Neko has shown that its clinic format can be copied across cities, while customer volume still rises with the number of scanning rooms and medical teams. Is Neko Health’s demand as strong as it looks? Neko’s demand is real today, although a waitlist signup and a prepaid return visit tell us very different things. A waitlist signup only shows interest. Neko now has more than 350,000 registrations, but the better evidence comes from people booking once clinics open. Vogue Business reported that its first London appointments disappeared within ten minutes and that the UK queue later remained around six figures. The 75% prepaid rebooking rate is much more persuasive. Customers are handing over money for another scan rather than merely saying they enjoyed the first one. Neko reported 80% when it had completed its first 10,000 scans, so retention has softened only slightly as the customer base became much larger. Registrations currently outnumber completed scans by roughly 3.5 to one. That leaves plenty of demand to serve, but we still need the missing conversion rate: when Neko opens near registered users, how many actually pay? We also need longer cohorts. Returning once after an interesting first scan is easier than paying for a fourth or fifth year of mostly normal results. Neko has clearly found a large group of affluent customers who want this service. We still do not know whether ordinary households will pay every year after several reassuring scans. If you want more recent data on this point, please see our latest preventive health screening market report . Can one Neko Health clinic make enough money? A busy Neko clinic can produce substantial revenue, but the company has not published enough cost data to show attractive clinic-level profits. Neko says its Spitalfields site can deliver up to 30,000 scans per year. At the current UK fee, full utilization would produce about £8.97 million in annual scan revenue. Manchester can handle 20,000 scans and Birmingham 25,000, equivalent to maximum scan revenue of roughly £5.98 million and £7.48 million. Those are respectable figures for individual healthcare sites. They also show the amount of infrastructure required. One million annual scans would need about 34 Spitalfields-sized clinics. Ten million would need roughly 334. We still cannot tell whether these sites make good money. Neko has not disclosed construction costs, equipment spending, utilization by clinic, payroll per scan, customer acquisition costs or how long a new site takes to repay its setup cost. The company also includes follow-up reviews, referral letters and some specialist work in the original price. The capacity figures show that one large clinic can become a meaningful business, while profitability remains unproven. Neko’s recent funding gives it room to build before every location pays for itself, and that same cash can hide weak economics for quite a while. Annual scan volume Large clinics required at maximum site capacity Gross scan revenue at the current UK price What it would represent 30,000 1 £8.97 million One large city clinic 1 million About 34 £299 million A major international network 10 million About 334 £2.99 billion One of the world’s largest clinic chains 100 million About 3,334 £29.9 billion Medical infrastructure on a vast scale Can Neko scan many more people without rushing the medicine? Neko can process more people as its software improves, but clinicians still limit how cheap and fast the service can become. The company has built four main proprietary devices for skin imaging, circulation and heart assessment. Its system takes more than 2,000 high-resolution skin images, processes blood on site and brings the results together before the consultation. More recently, it added body-composition measurements and wearable data from Apple Health without extending the one-hour visit. That engineering can remove repetitive work. Cameras can capture the same angles every time, algorithms can highlight unusual patterns, and software can prepare a clear review for the clinician. The next generation of Neko equipment is being rolled out in Stockholm with higher-fidelity data and a redesigned scan room. The medical workload remains substantial. Neko says its clinicians typically see around nine members a day. When the company had four UK clinics, it employed more than 350 medical staff there, including general practitioners, cardiologists, dermatologists and nurses. Some of those employees support follow-ups and central operations, so the figure cannot be divided neatly by appointment. Even so, Neko is plainly running a labor-intensive service. The number to watch is clinician time per completed customer. If software lets one doctor safely review several scans in parallel and spend less time on routine cases, margins can improve sharply. If each visit continues to need a long personal review plus specialist backup, the company will scale more like a premium clinic group than a technology platform. Is Neko Health cheap enough for ordinary people? At its current £299 UK price, Neko is affordable beside luxury health screening but expensive as a mass annual habit. The price sits in a clever middle ground. It is close to Function Health’s annual laboratory membership, which starts at 1,000. Neko adds a polished clinic, same-visit blood results, skin mapping, cardiovascular checks and a clinician consultation. For many customers, the fee feels reasonable once. Paying it every year is a different decision. A couple would spend £598 annually before any treatment, medication or follow-up outside Neko. That is manageable for affluent professionals and difficult for a large share of households. Neko’s chief executive has described the current product as “affordable luxury.” Vogue Business reported that customers average about 44 years old and that the early biohacking-heavy audience has broadened. Those details suggest a sizeable premium market, perhaps millions of people across rich cities, rather than immediate mass access. The price can fall through automation, cheaper clinic formats or narrower scan packages. Employers and insurers could also pay on behalf of users. Until one of those routes becomes meaningful, Neko will remain far more accessible than elite longevity medicine and far less universal than Spotify. Does a Neko Health scan actually catch dangerous disease? Yes, Neko’s published Stockholm results show a meaningful number of serious diagnoses, including cancers and heart conditions that customers did not know they had. In its second operating year, Neko analysed 4,362 scans. It found a previously unknown life-threatening condition in 54 people, or about one in every 81 scanned. The cases included 25 melanomas, 19 severe cardiovascular conditions, eight severe metabolic conditions and two serious blood diseases. A further 174 people, or 4%, received a significant diagnosis requiring medical attention. Another 52 had an early or reversible condition. Added together, Neko classified 6.4% of customers as having an important actionable finding. At one million scans, the same detection rate would mean about 12,000 people with potentially life-threatening findings. The actual rate may change in different countries and customer groups, but the Stockholm cohort is already large enough to show that Neko finds more than rare curiosities. These figures come from Neko’s own observational report rather than an independent controlled study. We can trust the documented diagnoses more than broader claims about lives saved, because we do not know what ordinary care would have found later or how outcomes changed. Result in Neko’s 4,362-scan cohort People Share of scans Examples No further medical follow-up 3,547 81.3% Healthy or already controlled Previously unknown life-threatening condition 54 1.2% Melanoma, severe heart disease, leukemia Significant condition 174 4.0% Hypertension, valve disease, diabetes Early or reversible condition 52 1.2% Prediabetes, elevated blood pressure Cleared after further testing 217 About 5% Skin, blood or cardiovascular checks How many Neko customers get worried for nothing? About one in twenty people in Neko’s published Stockholm cohort needed extra testing and was then cleared, which is large enough to take seriously. Neko referred 18.7% of the 4,362 customers for some form of follow-up. The final results included the serious and treatable diagnoses described above, while 217 people, or 4.9% of the full group, were cleared after extra skin, laboratory or cardiovascular checks. Another 27 were still being investigated, and 291 chose an outside provider or did not complete Neko’s follow-up. A negative follow-up does not mean the initial concern was careless. Screening works by investigating uncertain findings, and some harmless cases must be checked to find the dangerous ones. The practical burden grows quickly, though. A 4.9% clearance rate would create 49,000 additional workups per million scans. Medical guidelines remain cautious for that reason. The US Preventive Services Task Force recommends against ECG screening for low-risk adults without symptoms and says evidence is insufficient for medium- or high-risk adults. For routine visual skin screening of people without symptoms, it also says the overall balance of benefits and harms is still uncertain. Neko may perform better than isolated screening tests because it combines measurements, reviews findings internally and tracks changes over time. Its long-term credibility will depend on publishing how many biopsies, specialist visits and procedures follow each scan, alongside the serious conditions found. If you want more recent data on this point, please see our latest preventive health screening market report . Do people get healthier after a second Neko scan? Neko’s early repeat-scan data is encouraging, but we cannot yet tell how much of the improvement came from the service. The company studied 1,469 Stockholm members who returned roughly one year later. Across the full group, blood pressure, cholesterol and blood sugar improved by statistically significant amounts, while weight stayed broadly stable. People with hypertension, prediabetes or diabetes showed the clearest gains. A smaller group gives us another clue. Among 113 returning members who had previously received a severe or significant diagnosis, 87, or 77%, were healthy or had the condition under control at their next scan. Some had received treatment, while others changed habits after learning about their risk. Neko openly states that this was not a controlled scientific study. Returners selected themselves, knew their first results and may be more motivated than customers who did not come back. Medication, ordinary doctors and lifestyle changes all contributed, and there was no matched group showing what would have happened without Neko. Our reading today is that Neko appears useful for finding risks and prompting action. Evidence that annual scanning itself improves long-term health, reduces hospital admissions or extends life will take larger independent studies and several more years. What does Neko have that competitors cannot easily copy? Neko’s hardest-to-copy advantage today is the way its devices, clinic workflow, medical team and growing data set work together. Competitors can reproduce individual pieces. Function Health can order broad blood panels without running elaborate clinics. Prenuvo and Ezra can offer much deeper internal imaging through MRI. Dermatology software can map moles, while ordinary private clinics already perform ECGs, blood pressure checks and doctor consultations. Neko puts many of these tasks into one hour at one price. It designs and assembles its own devices in Stockholm, operates on-site laboratories, controls the app and trains clinicians around one repeatable process. Around three-quarters of the data in each scan reportedly comes from Neko-built equipment. The data becomes more valuable as customers return. The Financial Times reported that one scan produces roughly 15 gigabytes and that more than 90% of customers consent to AI use. Applied to the completed scan base, that points to a data collection on the order of 1.5 petabytes, although storage methods and scan versions will affect the real figure. Neko also added body composition and wearable integration lately, giving doctors information about sleep, movement and recovery between annual visits. This makes the product harder to reduce to a single body scan. This advantage could shrink. Medical feedback arrives slowly, customer groups may be biased toward affluent Europeans, and large healthcare providers can buy many similar technologies. Neko’s lead will last only if its integrated system produces fewer mistakes, faster visits and better outcomes than competitors assembling comparable tests. Will New York pr
Can Neko Health really scale like Spotify?
NewMarketPitch Team